NCT05684484View on ClinicalTrials.gov

Role of Roflumilast in Ulcerative Colitis

PHASE4CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

April 15, 2024

Study Completion Date

September 15, 2024

Conditions
Ulcerative Colitis
Interventions
DRUG

Roflumilast 500 MCG Oral Tablet [DALIRESP]

Roflumilast has been approved by U.S. Food and Drug Administration (FDA) for attenuating bronchial and dermatological disorders

DRUG

amino salicylic acid

conventional treatment

Trial Locations (1)

002

faculty of pharmacy Tanta university, Tanta

All Listed Sponsors
lead

Tanta University

OTHER